Comprehensive Physiology Wiley Online Library
For Librarians For Authors Editors About

Insulin‐like Growth Factor‐1 and the Endocrine Pancreas

David G. Maggs, Robert S. Sherwin

10.1002/cphy.cp070230

Source: Supplement 21: Handbook of Physiology, The Endocrine System, The Endocrine Pancreas and Regulation of Metabolism

Originally published: 2001

Published online: January 2011

Full Article on Wiley Online Library



Abstract

The sections in this article are:

1 Insulin‐like Growth Factor‐1 and Pancreatic Islet Growth, Development, and Regeneration
2 Insulin‐like Growth Factor‐1 and Regulation of Pancreatic Islet Function
3 Insulin‐like Growth Factor Binding Proteins and The Pancreatic Islet
4 Summary
Figure 1. Figure 1.

Comparable effects of continuous intravenous IGF‐1 (0.8μg/kg/min) and insulin (0.8 mU/kg/min) on glucose uptake and production during clamped euglycemic conditions in nonobese, healthy volunteers (n = 21, aged 20–34 yr). Basal data are included for comparison.

[Adapted from Boulware et al. 6.]
Figure 2. Figure 2.

Effect of 120 min primed‐continuous infusion of either IGF‐1 (0.7 μg/kg/min) or insulin (0.8 mU/kg/min) on plasma glucose, glucagon, and growth hormone in nonobese, healthy volunteers (n = 18, aged 18–33 yr). Note the equivalent hypoglycemic stimulus with IGF‐1 and insulin, but impaired glucagon and growth hormone responses and delayed glucose recovery with IGF‐1.

[Adapted from Kerr et al. 35.]
Figure 3. Figure 3.

Suppression of endogenous insulin secretion by IGF‐1 (0.4 μg/kg/min) with plasma glucose clamped at 8 and 13 mM during hyperglycemic clamp procedure in nonobese, healthy volunteers (n = 14, aged 18–34 yr).

[Adapted from Rennert et al. 67.]


Figure 1.

Comparable effects of continuous intravenous IGF‐1 (0.8μg/kg/min) and insulin (0.8 mU/kg/min) on glucose uptake and production during clamped euglycemic conditions in nonobese, healthy volunteers (n = 21, aged 20–34 yr). Basal data are included for comparison.

[Adapted from Boulware et al. 6.]


Figure 2.

Effect of 120 min primed‐continuous infusion of either IGF‐1 (0.7 μg/kg/min) or insulin (0.8 mU/kg/min) on plasma glucose, glucagon, and growth hormone in nonobese, healthy volunteers (n = 18, aged 18–33 yr). Note the equivalent hypoglycemic stimulus with IGF‐1 and insulin, but impaired glucagon and growth hormone responses and delayed glucose recovery with IGF‐1.

[Adapted from Kerr et al. 35.]


Figure 3.

Suppression of endogenous insulin secretion by IGF‐1 (0.4 μg/kg/min) with plasma glucose clamped at 8 and 13 mM during hyperglycemic clamp procedure in nonobese, healthy volunteers (n = 14, aged 18–34 yr).

[Adapted from Rennert et al. 67.]
References
 1. Abe, H., M. Molitch, J. Van Wyk, and L. Underwood. Human growth hormone and somatomedin C suppress release of growth hormone in unanesthesized rats. Endocrinology 113: 1319–1327, 1983.
 2. Atkinson, M., N. MacLaren, and R. Luchetta. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39: 933–937, 1990.
 3. Baker, J., J. Lie, E. Robertson, and A. Efstratiadis. Role of the insulin‐like growth factors in embryonic and postnatal growth. Cell 75: 73–82, 1993.
 4. Bar, R., D. Clemmons, M. Boes, W. Busby, B. Booth, B. Dake, and A. Sandra. Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin‐like growth factor binding proteins in the rat heart. Endocrinology 127: 1078–1086, 1990.
 5. Bedossa, P., A. Bendelac, J. Bach, and C. Carnaud. Syngeneic T cell transfer of diabetes into NOD newborn mice: in situ studies of the autoimmune steps leading to insulin producing cell destruction. Eur. J. Immunol. 19: 1947–1951, 1989.
 6. Bergerot, I., N. Fabien, V. Maguer, and C. Thivolet. Insulin‐like growth factor‐1 (IGF‐1) protects NOD mice from insulitis and diabetes. Clin. Exp. Immunol. 102: 335–340, 1995.
 7. Bermann, M., C. A. Jaffe, T. Wellington, R. De Mott‐Friberg, and A. L. Barkan. Negative feedback regulation of pulsatile growth hormone secretion by insulin‐like growth factor 1. J. Clin. Invest. 94: 138–145, 1994.
 8. Bertrand, S., M. De Paepe, C. Vigeant, and J. Yale. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 41: 1273–1277, 1990.
 9. Binz, K., P. Joller, P. Froesch, H. Binz, J. Zapf, and E. Froesch. Repopulation of the atrophied thymus in diabetic rats by insulin like growth factor I. Proc. Natl. Acad. Sci. USA 87: 3690–3694, 1990.
 10. Boulware, S., W. Tamborlane, L. Matthews, and R. Sherwin. Diverse effects of insulin‐like growth factor I on glucose, lipid, and amino acid metabolism. Am. J. Physiol. Endocrinol. Metab. 262: Ei30–Ei33, 1992.
 11. Brunicardi, F., J. Stagner, S. Bonner‐Weir, H. Wayland, R. Kleinman, E. Livingston, P. Guth, M. Menger, R. McCuskey, M. Intaglietta, A. Charles, S. Ashley, A. Cheung, E. Ipp, S. Gilman, T. Howard, and E. Passaro Jr.. Microcirculation of the islets of Langerhans. Diabetes 45: 1996.
 12. Burch, W., J. Correa, J. Shively, and D.J.O.C.E. & M. Powell. The 25–kilodalton insulin‐like growth factor (IGF)‐binding protein inhibits both basal and IGF‐I‐mediated growth of chick embryo pelvic cartilage in vitro. J. Clin. Endocrinol. Metab. 70: 173–180, 1990.
 13. Busby, W., D. Klapper, and D. Clemmons. Purification of a 31000 dalton insulin like growth factor binding protein from human amniotic fluid. J. Biol. Chem. 263: 14203–14210, 1988.
 14. Caro, J., J. Poulos, O. Ittoop, W. Pories, E. Flickinger, and M. Sinha. Insulin‐like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating fetal liver. J. Clin. Invest. 81: 976–981, 1988.
 15. Clark, R., J. Strasse, S. McCabe, K. Robbins, and P. Jardieu. Insulinlike growth factor‐1 stimulation of lymphopoiesis. J. Clin. Invest. 92: 540–548, 1993.
 16. Clark, S., and W. Chick. Islet cell culture in defined serum‐free medium. Endocrinology 126: 1895–1903, 1990.
 17. Clemmons, D.. Insulin‐like growth factor binding proteins. Trends Endocrinol. Metab. 1: 412–417, 1990.
 18. Conover, C., and P. Lee. Insulin regulation of insulin‐like growth factor‐binding protein production in cultured HepG2 cells. J. Clin. Endocrinol. Metab. 70: 1062–1067, 1990.
 19. Cotterill, A., J. Holly, S. Amiel, and J. Wass. Suppression of endogenous insulin secretion regulates the rapid rise of insulin‐like growth factor binding protein (IGFBP)‐1 levels following acute hypoglycemia. Clin. Endocrinol. 38: 633–639, 1993.
 20. Daughaday, W., and P. Rotwein. Insulin‐like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrinol. Rev. 10: 68–90, 1989.
 21. De Chiari, T., A. Efstratiadis, and E. Robertson. A growth deficiency phenotype in heterozygous mice carrying an insulin‐like factor II gene disrupted by gene targeting. Nature Lond. 345: 78–80, 1990.
 22. Dheen, S. T., K. Rajkumar, and L. Murphy. Effects of insulin‐like growth factors (IGF) on pancreatic islet action in IGF binding protein‐1 transgenic mice. Diabetologia 39: 1249–1254, 1996.
 23. Eckhoff, D., H. Sollinger, and D. Hullet. Selective enhancement of B cell activity by preparation of fetal pancreatic proislets and culture with insulin growth factor. Transplantation 51: 1161–1165, 1991.
 24. Elgin, G., W. Busby, and D. Clemmons. An insulin‐like growth factor (IGF) binding protein enhances the biologic responses to IGF‐1. Proc. Natl. Acad. Sci. USA 84: 3254–3258, 1987.
 25. Fehmann, H., P. Jehle, U. Markus, and B. Goke. Functional active receptors for insulin‐like growth factor‐I (IGF‐1) and IGF‐II on insulin‐, glucagon‐, and somatostatin‐producing cells. Metabolism 45: 759–766, 1996.
 26. Guler, H., C. Schmid, J. Zapf, and E. Froesch. Effects of recombinant insulin‐like growth factor I on insulin secretion and renal function in normal human subjects. Proc. Natl. Acad. Sci. USA 86: 2868–2872, 1989.
 27. Guler, H., J. Zapf, and E. Froesch. Short‐term metabolic effects of recombinant human insulin‐like growth factor I in healthy adults. N. Engl. J. Med. 317: 137–140, 1987.
 28. Han, V., P. Lund, D. Lee, and A. D'Ercole. Expression of somatomedin/insulin‐like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. J. Clin. Endocrinol. Metab. 66: 422–429, 1988.
 29. Hill, D., A. Frazer, I. Swenne, P. Wirdnam, and R. Milner. Somatomedin‐C in human fetal pancreas. Cellular localization and release during organ culture. Diabetes 36: 465–471, 1987.
 30. Hogg, J., V. Han, D. Clemmons, and D. Hill. Interactions of nutrients, insulin‐like growth factors (IGFs) and IGF‐binding proteins in the regulation of DNA synthesis by isolated fetal rat islets of Langerhans. J. Endocrinol 138: 410–412, 1993.
 31. Hogg, J., D. Hill, and V. Han. The ontogeny of insulin‐like growth factor (IGF) and IGF‐binding protein gene expression in the rat pancreas. J. Mol. Endocrinol. 13: 49–58, 1994.
 32. Hussain, M., O. Schmitz, J. Christiansen, N. Christiansen, G. Alberti, and R. Froesch. IGF‐1 alters skeletal muscle substrate metabolism and blunts recovery from insulin‐induced hypoglycemia. Am. J. Physiol. 270: E545–E551, 1996.
 33. Hussain, M., O. Schmitz, A. Mengel, A. Keller, J. Christiansen, J. Zapf, and E. Froesch. Insulin‐like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J. Clin. Invest. 92: 2249–2256, 1993.
 34. Jacob, R., E. Barrett, G. Plewe, K. Fagin, and Sherwin, R. S.. Acute effects of recombinant human insulin‐like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J. Clin. Invest. 83: 1717–1723, 1989.
 35. Kerr, D., W. Tamborlane, F. Rife, and R. Sherwin. Effect of insulinlike growth factor‐1 on the responses to and recognition of hypoglycemia in humans. J. Clin. Invest. 91: 141–147, 1993.
 36. Klaff, L., B. Dunning, and G. J. Taborsky. Somatostatin‐28 does not regulate islet function in the dog. Endocrinology 123: 2668–2674, 1988.
 37. Kulik, G., A. Klippel, and M. Weber. Anti‐apoptotic signalling by the insulin‐like growth factor I receptor, phosphatidylinositol 3–kinase, and Akt. Mol. Cell. Biol. 17: 1595–1606, 1997.
 38. Kurrer, M., S. Pakala, H. Hanson, and J. Katz. Beta cell apoptosis in T cell‐mediated autoimmune diabetes. Proc. Natl. Acad. Sci. USA 94: 213—218, 1997.
 39. Laager, R., and U. Keller. Effects of recombinant human insulinlike growth factor‐I on counterregulation during acute plasma glucose decrements in normal and type II (non‐insulin dependent) diabetic subjects. Diabetologia 36: 391–396, 1993.
 40. Leahy, J. L., and K. M. Vanderkerkhove. Insulin‐like growth factor‐1 at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593–1598, 1990.
 41. Lee, P., M. Jensen, G. Divertie, V. Heiling, H. Katz, and C. Conover. Insulin‐like growth factor‐binding protein‐1 response to insulin during suppression of endogenous insulin secretion. Metabolism 42: 409–414, 1993.
 42. Lewitt, M., and R. Baxter. Regulation of growth hormone independent insulin‐like growth factor binding protein (BP‐28) in cultured human fetal liver explants. J. Clin. Endocrinol. Metab. 69: 246–252, 1989.
 43. Lewitt, M., G. Denyer, G. Cooney, and R. Baxter. Insulin‐like growth factor binding protein‐1 modulates blood glucose levels. Endocrinology 129: 2254–2259, 1991.
 44. Lifson, N., C. Lassa, and P. Dixit. Relation between blood flow and morphology in islet organ of rat pancreas. Am. J. Physiol. 249: E43–E48, 1985.
 45. Like, A.. Insulin injections prevent diabetes (DB) in biobreeding/Worcester (BB/Wor) rats. Diabetes 35 (Suppl 1): 74, 1986.
 46. Liu, J., J. Baker, A. Perkins, E. Robertson, and A. Efstratiadis. Mice carrying null mutations of the genes encoding insulin‐like growth factor I (IGF‐1) and type I IGF receptor (IGFlr). Cell 75: 59–72, 1993.
 47. Liu, L., A. Brinkman, C. Blat, and L. Harel. IGFBP‐1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem. Biophys. Res. Commun. 174: 673–679, 1991.
 48. Liu, Q., D. Schacher, C. Hurth, G. Freund, R. Dantzer, and K. Kelley. Activation of phosphatidylinositol 3′‐kinase by insulin‐like growth factor I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes. J. Immunol. 159: 829–837, 1997.
 49. Maake, C., and M. Reinecke. Immunohistochemical localization of insulin‐like growth factor 1 and 2 in the endocrine pancreas of rat, dog, and man, and their coexistence with classical islet hormones. Cell Tissue Res. 273: 249–259, 1993.
 50. Mathews, L., R. Hammer, R. Behringer, A. D'Ercole, G. Bell, R. Brinster, and R. Palmiter. Growth enhancement of transgenic mice expressing human insulin‐like growth factor. Endocrinology 123: 2827–2833, 1988.
 51. Mathews, L., G. Norstedt, and R. Palmiter. Regulation of insulinlike growth factor‐I gene expression by growth hormone. Proc. Natl. Acad. Sci. USA 83: 9343–9347, 1986.
 52. McCusker, R., and D. Clemmons. In: The Insulin‐like Growth Factor Binding Proteins: Structure and Biological Functions, edited by P. Schofield. New York: Oxford University Press, p. 110–150, 1992.
 53. Morgan, J., S. Saris, D. Capuzzi, W. Good, V. John, H. Guler, J. Seaman, D. Pharm, and A. Piraino. Hypoglycemic and insulin response to a continuous intravenous infusion of CGP‐35126 recombinant human insulin‐like growth factor‐1 (9rhIGF‐1) in healthy males. J. Clin. Pharmacol. 33: 366–372, 1993.
 54. D., Mortensen, W. Won, J. Siu, D. Reifsynder, M. Gironella, T. Etcheverry, and R. Clark. Insulin‐like growth factor binding protein‐1 induces insulin release in the rat. Endocrinology 138: 2073–2080, 1997.
 55. O'Brien, B., B. Harmon, D. Cameron, and D. Allan. Beta‐cell apoptosis is responsible for the development of IDDM in the multiple low‐dose streptozotocin model. J. Pathol. 178: 178–181, 1996.
 56. O'Brien, B., B. Harmon, D. Cameron, and D. Allan. Apoptosis is the mode of beta‐cell death responsible for the development of IDDM in the nonobese (NOD) mouse. Diabetes 46: 750–757, 1997.
 57. Palmiter, R., G. Norstedt, R. Gelinas, R. Hammer, and R. Brinster. Metallothionein‐human GH fusion genes stimulate growth of mice. Science 222: 809–814, 1983.
 58. Parrizas, M., A. Saltiel, and D. LeRoith. Insulin‐like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′‐kinase and mitogen‐activated protein kinase pathways. J. Biol. Chem. 272: 154–161, 1997.
 59. Plisetskaya, E.. Pancreatic peptides. In: The Comparative Physiology of Regulatory Peptides, edited by S. Holmgren. London: Chapman and Hall, p. 174–202, 1989.
 60. Poggi. C., Y. Le Marchand‐Brustel, J. Zapf, E. Froesch, and P. Freychet. Effects and binding of insulin‐like growth factor in the isolated soleus muscle of lean and obese mice. Endcrinology 195: 723–730, 1979.
 61. Porksen, N., M. Hussain, T. Bianda, B. Nyholm, J. Christiansen, P. Butler, J. Veldhuis, E. Froesch, and O. Schmitz. IGF‐1 inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF‐1 infusion rates. Am. J. Physiol. 272: E352–E358, 1997.
 62. Porksen, N., S. Munn, J. Steers, J. D. Veldhuis, and P. C. Butler. Effects of somatostatin on pulsatile insulin secretion: elective inhibition of insulin burst mass. Am. J. Physiol. 270: E1043–E1049, 1996.
 63. Porksen, N., S. Munn, J. Steers, S. Vore, J. D. Veldhuis, and P. C. Butler. A pusatile mode of insulin secretion accounts for approximately seventy percent of total insulin secreted during fasting: direct in vivo measurement by two newly validated independent methods. Am. J. Physiol. 269: E478–E488, 1995.
 64. Quaife, C., L. Mathews, C. Pinkert, R. Hammer, R. Brinster, and R. Palmiter. Histopathology associated with elevated levels of growth hormone and insulin‐like growth factor I in transgenic mice. Endocrinology 124: 40–48, 1989.
 65. Rajkumar, K., D. Barron, M. Lewitt, and L. Murphy. Growth retardation and hyperglycemia in insulin‐like growth factor binding protein‐1 transgenic mice. Endcrinology 136: 4029–4034, 1995.
 66. Rajkumar, K., S. Dheen, and L. Murphy. Hyperglycemia and impaired glucose tolerance in insulin‐like growth factor binding protein‐1 transgenic mice. Am. J. Physiol. 270: E565–E571, 1996.
 67. Rennert, N., S. Caprio, and R. Sherwin. Insulin‐like growth factor I inhibits glucose‐stimulated insulin secretion but does not impair glucose metabolism in normal humans. J. Clin. Endocrinol. Metab. 76: 804–806, 1993.
 68. Ritvos, O., T. Ranta, J. Jalkanen, A. Suikkari, R. Voutilainen, H. Bohn, and E. Rutanen. Insulin‐like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF‐1 in cultured choriocarcinoma cells. Endocrinology 122: 2150–2157, 1988.
 69. Romanus, J., A. Rabinovitch, and M. Rechler. Neonatal rat islet cell cultures synthesize insulin‐like growth factors and their binding proteins. Diabetes 34: 696–702, 1985.
 70. Ross, M., G. Francis, L. Szabo, J. Wallace, and F. Ballard. Insulinlike growth factor (IGF)‐binding proteins inhibit the biological activities of IGF‐1 and IGF‐2 but not des‐(1–3)‐IGF‐1. Biochem. J. 258: 267–272, 1989.
 71. Rutanen, E., F. Pekonen, and T. Makinen. Soluble 34K binding protein inhibits the binding of insulin‐like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J. Clin. Endocrinol. Metab. 66: 173–180, 1988.
 72. Samols, E., and J. Stagner. Intraislet and islet‐acinar portal systems and their significance. In: The Endocrine Pancreas, edited by E. Samols. New York: Raven Press, p. 93–124, 1991.
 73. Sara, V., and K. Hall. The insulin‐like growth factors and their binding proteins. Physiol. Rev. 70: 591–614, 1990.
 74. Scaglia, L., F. Smith, and S. Bonner‐Weir. Apoptosis contributes to the involution of beta cell mass in the postpartum rat pancreas. Endocrinology 136: 5461–5468, 1995.
 75. Scharfmann, R., M. Corvol, and P. Czernichow. Characterization of insulin‐like growth factor I produced by fetal rat pancreatic islets. Diabetes 38: 686–690, 1989.
 76. Sieradzki, J., H. Fleck, A. Chatterjee, and H. Schatz. Stimulatory effect of insulin‐like growth factor‐1 on [3H; chthymidine incorporation, DNA content and insulin biosynthesis and secretion of isolated pancreatic islets. J. Endocrinol. 177: 59–62, 1988.
 77. Smith, F., K. Rosen, L. Villa‐Komaroff, G. Weir, and S. Bonner‐Weir. Enhanced insulin‐like growth factor‐1 gene expression in regenerating rat pancreas. Cell Biol. 88: 6152–6156, 1991.
 78. Stagner, J., E. Samols, and S. Bonner‐Weir. B‐A‐D pancreatic islet cellular perfusion in dogs. Diabetes 41: 1715–1721, 1988.
 79. Suikkari, A., V. Koivisto, R. Koistinen, M. Seppala, and H. Yki‐Jarvinen. Dose‐response characteristics for suppression of low molecular weight plasma insulin‐like growth factor‐binding protein by insulin. J. Clin. Endocrinol. Metab. 68: 135–140, 1989.
 80. Suikkari, A., V. Koivisto, E. Rutanen, E. Rutanen, H. Yki‐Jarvinen, S. Karonen, and M. Seppala. Insulin regulates the serum levels of low molecular weight insulin‐like growth factor‐binding protein. J. Clin. Endocrinol. Metab. 66: 266–272, 1988.
 81. Tagami, M., K. Ikeda, Y. Nara, H. Fujino, A. Kubota, F. Numano, and Y. Yamori. Insulin‐like growth factor I attenuates apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke‐prone spontaneously hypertensive rats. Lab. Invest. 76: 613–617, 1997.
 82. Thivolet, C., E. Goillot, P. Bedossa, A. Durand, M. Bonnard, and J. Orgiazzi. Insulin prevents adoptive cell transfer of diabetes in the autoimmune non‐obese diabetic mouse. Diabetologia 34: 314–319, 1991.
 83. Timsit, J., W. Savino, B. Safieh, P. Chanson, M. Gagnerault, J. Bach, and M. Dardenne. Growth hormone and insulin like factor I stimulate hormonal function and proliferation of thymic epithelial cells. Endocrinol. Metab. 75: 183–188, 1992.
 84. Turkalj, I., U. Keller, R. Ninnis, S. Vosmeer, and W. Stauffacher. Effect of increasing doses of recombinant human insulin‐like growth factor‐1 on glucose, lipid, and leucine metabolism in man. J. Clin. Endocrinol. Metab. 75: 1186–1191, 1992.
 85. Van Schravendijk, C., A. Foriers, J. Van den Brande, and D. Pipeelers. Evidence for the presence of type I insulin‐like growth factor receptors on rat A and B‐cells. Endocrinology 121: 1784–1788, 1987.
 86. Van Schravendijk, C., L. Heylen, J. Van den Brande, and D. Pipeleers. Direct effect of insulin and insulin‐like growth factor I on the secretory activity of rat pancreatic beta cells. Diabetologia 33: 649–653, 1990.
 87. Welsh, M., N. Welsh, K. Bendtzen, J. Mares, E. Strandell, C. Oberg, and S. Sandler. Comparison of mRNA contents of interleukin‐1ã and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice. Diabetologia 38: 153–160, 1995.
 88. Wong, H., J. Walsh, H. Yang, Y. Tache, and A. Buchan. A monoclonal antibody to somatostatin with potent in vivo immunoneutralizing activity. Peptides 11: 707–712, 1990.
 89. Zapf, J., E. Schoenle, M. Waldvogel, I. Sand, and E. Froesch. Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin‐like growth factors: further evidence for the action of insulin‐like growth factors through the insulin receptor. Eur. J. Biochem. 113: 605–609, 1981.
 90. Zenobi, P., S. Graf, H. Ursprung, and E. Froesch. Effects of insulinlike growth factor‐1 on glucose tolerance, insulin levels, and insulin secretion. J. Clin. Invest. 89: 1908–1913, 1992.

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Insulin‐like Growth Factor‐1 and the Endocrine Pancreas
 

How to Cite

David G. Maggs, Robert S. Sherwin. Insulin‐like Growth Factor‐1 and the Endocrine Pancreas. Compr Physiol 2011, Supplement 21: Handbook of Physiology, The Endocrine System, The Endocrine Pancreas and Regulation of Metabolism: 939-948. First published in print 2001. doi: 10.1002/cphy.cp070230